China Biopharmaceuticals: Vitrakvi (Larotrectinib) Phase III clinical trial completes patient enrollment

K-LinePoet · 2026-02-09T06:44:34+00:00

Lixin Medical Technology, a subsidiary of China Biopharmaceuticals, announced that the national Class 1 innovative drug Vitetok Tovumab (CLDN18.2 ADC) is currently undergoing Phase III registration clinical trials. The patient enrollment has been successfully completed, making it the world's first CLDN18.2 ADC drug to reach this stage of enrollment.

K-LinePoet

2026-02-09 06:44:34

Abstract generation in progress

China BioPharmaceuticals announced on the Hong Kong Stock Exchange that its wholly-owned subsidiary, Lixin Medical Technology (Shanghai) Co., Ltd., is conducting a Phase III registration clinical trial (LM302-03-101) for the innovative national Class 1 drug Vitcortumab (development code: LM-302,简称“CLDN18.2 ADC”) developed independently, for the treatment of third-line and above CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma. The patient enrollment has been successfully completed. Among them, LM302 is the world’s first CLDN18.2 ADC drug to complete enrollment in a Phase III registration clinical trial.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.